Todos os posts

Critério de classificação ACR/EULAR 2022 para arterite de Takayasu.

13 Dez, 2022 | 15:17h

2022 American College of Rheumatology/EULAR classification criteria for Takayasu arteritis – Annals of the Rheumatic Diseases

Comunicado de imprensa: Classification criteria established for Takayasu arteritis – European Alliance of Associations for Rheumatology, EULAR

 

---

Estudo randomizado | Uso de zinco por via oral 2 vezes/dia no tratamento de pacientes com COVID-19.

13 Dez, 2022 | 15:16h

Twice-Daily Oral Zinc in the Treatment of Patients With Coronavirus Disease 2019: A Randomized Double-Blind Controlled Trial – Clinical Infectious Diseases

 

---

Revisão | Gastroenterologia intervencionista na oncologia.

13 Dez, 2022 | 15:15h

Interventional gastroenterology in oncology – CA: A Cancer Journal for Clinicians

 

---

Revisão sistemática | Caracterização do uso problemático do álcool entre médicos.

13 Dez, 2022 | 15:13h

Characterization of Problematic Alcohol Use Among Physicians: A Systematic Review – JAMA Network Open

 

---

Comparação de resultados de estudos clínicos divulgados em pré-prints do medRxiv vs. artigos subsequentemente publicados e revisados por pares.

13 Dez, 2022 | 15:12h

Comparison of Clinical Study Results Reported in medRxiv Preprints vs Peer-reviewed Journal Articles – JAMA Network Open

Entrevista com os autores: Clinical Study Results Reported in medRxiv Preprints vs Peer-reviewed Journals

 

---

Posicionamento científico UEG | Obesidade e saúde digestiva.

13 Dez, 2022 | 15:11h

UEG position paper: Obesity and digestive health – UEG Journal

 

---

Estudo randomizado | Filme de mepitel na prevenção de dermatite aguda por radiação no câncer de mama.

13 Dez, 2022 | 15:10h

Mepitel Film for the Prevention of Acute Radiation Dermatitis in Breast Cancer: A Randomized Multicenter Open-Label Phase III Trial – Journal of Clinical Oncology (link para o resumo – $ para o texto completo)

 

---

Estudo de braço único, fase 1 | Talquetamabe, um anticorpo biespecífico GPRC5D de redirecionamento de célula T, para mieloma múltiplo.

13 Dez, 2022 | 15:08h

Talquetamab, a T-Cell–Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma – New England Journal of Medicine (link para o resumo – $ para o texto completo)

Comentário: More Than 70% of Heavily Pretreated Patients Taking Talquetamab for Multiple Myeloma See Responses That “Deepen Over Time” – AJMC

 

Comentário no Twitter

Talquetamab, a bifunctional antibody, directs activated T cells to tumor. In this study, up to 70% of the patients with relapsed or refractory myeloma had a response to this agent. https://t.co/OJGHobKG0E pic.twitter.com/53soLSCepA

— NEJM (@NEJM) December 10, 2022

 

---

Estudo de braço único, fase 1/2 | Glofitamabe para linfoma recidivante ou refratário de grandes células B.

13 Dez, 2022 | 15:07h

Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma – New England Journal of Medicine (link para o resumo – $ para o texto completo)

 

Comentário no Twitter

Glofitamab, a bifunctional antibody, was given to 154 patients with relapsed or refractory DLBCL. Complete response occurred in 39%; most of these responses were ongoing at 12 months. Cytokine release syndrome was common. https://t.co/FWavXlkVXD pic.twitter.com/F4eyYja2E4

— NEJM (@NEJM) December 11, 2022

 

---

Breve revisão | Diagnóstico e tratamento da gastroparesia.

13 Dez, 2022 | 15:06h

Diagnosis and Management of Gastroparesis – The American Journal of Gastroenterology

Conteúdos relacionados:

Worldwide prevalence and burden of gastroparesis-like symptoms.

ACG Clinical Guideline: Gastroparesis – The American Journal of Gastroenterology

United European Gastroenterology (UEG) and European Society for Neurogastroenterology and Motility (ESNM) consensus on gastroparesis – UEG Journal

 

---